Global western blotting market is projected to reach USD 1.4 billion by 2026 from USD 1.0 billion in 2021, at a CAGR of 6.7% during the forecast period. North America accounted for the largest share of the western blotting market.

Request For Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=235810711

Technological advancements, increasing government funding in the field of biomedical research, growing demand for personalized medicine, and the rising prevalence of HIV are the key factors driving the market growth.

Key Market Players

The western blotting market is dominated by a few globally established players such as Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Techne Corporation (US), and Merck KGaA (Germany) are the prominent players operating in the western blotting market.

BIO-RAD LABORATORIES, INC. (US)

Bio-Rad Laboratories is a leading player in the western blotting market in 2020. The company is a leading manufacturer and supplier of products and systems to separate, detect, analyze, and purify complex biological and chemical materials. The company’s leading position in the market can be attributed to its wide customer base.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=235810711

THERMO FISHER SCIENTIFIC INC. (US)

Thermo Fisher Scientific held the second position in the western blotting market in 2020. The company provides a wide range of products in this market, including protein gels, protein standards ladders, protein electrophoresis buffers reagents, protein gel electrophoresis chamber systems, power supplies for protein electrophoresis, and protein gel staining and imaging products. These products are made available through Thermo Fisher Scientific’s broad sales force and global network of resellers and distributors.

Recent Developments

• In September 2021, PerkinElmer, Inc. (US) acquired BioLegend (US), a leading provider of life science antibodies and reagents, including primary antibodies and western blot secondary reagents. This acquisition enhances the company’s existing western blotting product portfolio.
• In August 2021, Abcam Plc (UK) acquired BioVision Inc. (US), a global supplier of life science research tools for research, diagnostics, and drug discovery. The company is a leading provider of biochemical and cell-based assays and produces a wide portfolio of other products, including recombinant proteins, antibodies, enzymes, and biochemical compounds for immunoassay technologies such as western blotting
• In April 2021, Bio-Techne Corporation (US) launched Abby, a next-generation chemiluminescence system that automates traditional western blotting
• In October 2020, Bio-Techne Corporation (US) launched a SARS-CoV-2 Multi-Antigen Serology Module for Jess and Wes Simple Western automated western blotting systems. The new serology assay accelerates COVID-19 research and vaccine development through rapid characterization of human immune responses to multiple SARS-CoV-2 antigens
• Merck KGaA (Germany) introduced a national campus tour in China for the company’s first mobile protein research laboratory. The national tour will cover 20 college and biotech campuses in 13 cities across the country, including Beijing, Chengdu, Guangzhou, and Wuhan.

Request For Custom Research @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=235810711